Skip to main content
Erschienen in: International Urogynecology Journal 12/2017

04.04.2017 | Original Article

Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder

verfasst von: Alexandra I. Barsdorf, Martin Carlsson, Andrew G. Bushmakin, Sheila Quinn, Joseph C. Cappelleri, Andreas Pleil

Erschienen in: International Urogynecology Journal | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The 33-item Overactive Bladder questionnaire (OAB-q; 1-week recall version) has been psychometrically validated in middle-aged, generally healthy patients with overactive bladder. The present analysis was conducted to determine the psychometric validity of the OAB-q in medically complex elderly patients.

Methods

OAB-q structure was evaluated using a second-order confirmatory factor analysis (CFA) model with five domains and one aggregated domain, using pooled data from two clinical trials (786 observations) for urgency urinary incontinence (UUI). Psychometric validity was evaluated with CFA, Cronbach coefficient α (CCA) for reliability, Spearman correlations for convergent validity, differences in OAB-q scores in relation to UUI severity and Patient Perception of Bladder Condition (PPBC) scores for known-groups validity, and effect size (ES) of differences in mean scores of OAB-q domains over time for treatment responsiveness.

Results

Participants were predominantly female (82.2%) and white (85.9%); mean age was 75.0 years. The second-order CFA was confirmed with a Bentler’s comparative fit index of 0.90, t values for path coefficients of >1.96, and standardized path coefficients of >0.40. OAB-q domains demonstrated good internal consistency (CCA >0.7). Convergent validity was supported by moderate correlations (0.4–0.7) between OAB-q domain and PPBC scores. Significant differences in OAB-q domain scores between groups with different symptom severity established known-groups validity. Significant changes in mean OAB-q scores from baseline to week 12 with moderate-to-large ES (0.50–0.80) demonstrated treatment responsiveness.

Conclusions

The OAB-q demonstrates reliability, concurrent and discriminant validity, and responsiveness to treatment. The evidence shows that the OAB-q is psychometrically sound for use in medically complex elderly patients with overactive bladder.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002;187:116–126.CrossRefPubMed Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002;187:116–126.CrossRefPubMed
2.
Zurück zum Zitat Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001;57:1044–1050.CrossRefPubMed Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001;57:1044–1050.CrossRefPubMed
3.
Zurück zum Zitat Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97:96–100.CrossRefPubMed Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97:96–100.CrossRefPubMed
4.
Zurück zum Zitat Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108:1459–1471.CrossRefPubMed Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108:1459–1471.CrossRefPubMed
5.
Zurück zum Zitat Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol. 2010;57:586–591.CrossRefPubMed Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol. 2010;57:586–591.CrossRefPubMed
6.
Zurück zum Zitat Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314. discussion 1314-5. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314. discussion 1314-5.
7.
Zurück zum Zitat Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77:1081–1087.CrossRefPubMed Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77:1081–1087.CrossRefPubMed
8.
Zurück zum Zitat Chancellor MB, de Miguel F. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics. 2007;62:15–24.PubMed Chancellor MB, de Miguel F. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics. 2007;62:15–24.PubMed
9.
Zurück zum Zitat Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133–143.CrossRefPubMed Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133–143.CrossRefPubMed
10.
Zurück zum Zitat Gibson W, Athanasopoulos A, Goldman H et al. Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence? Int J Clin Pract. 2014;68:1165–1173. Gibson W, Athanasopoulos A, Goldman H et al. Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence? Int J Clin Pract. 2014;68:1165–1173.
11.
Zurück zum Zitat U.S. Department of Health and Human Services. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2009. U.S. Department of Health and Human Services. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2009.
12.
Zurück zum Zitat Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Boca Raton: Chapman & Hall; 2013. Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Boca Raton: Chapman & Hall; 2013.
13.
Zurück zum Zitat Saliba D, Elliott M, Rubenstein LZ et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–1699.CrossRefPubMed Saliba D, Elliott M, Rubenstein LZ et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–1699.CrossRefPubMed
14.
Zurück zum Zitat Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11:563–574.CrossRefPubMed Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11:563–574.CrossRefPubMed
15.
Zurück zum Zitat Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005;14:849–855.CrossRefPubMed Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005;14:849–855.CrossRefPubMed
16.
Zurück zum Zitat Coyne KS, Gelhorn H, Thompson C, Kopp ZS, Guan Z. The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J. 2011;22:1555–1563.CrossRefPubMed Coyne KS, Gelhorn H, Thompson C, Kopp ZS, Guan Z. The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J. 2011;22:1555–1563.CrossRefPubMed
17.
Zurück zum Zitat Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49:1079–1086.CrossRefPubMed Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49:1079–1086.CrossRefPubMed
18.
Zurück zum Zitat Coyne KS, Margolis MK, Hsieh R, Vats V, Chapple CR. Validation of the urinary sensation scale (USS). Neurourol Urodyn. 2011;30:360–365.CrossRefPubMed Coyne KS, Margolis MK, Hsieh R, Vats V, Chapple CR. Validation of the urinary sensation scale (USS). Neurourol Urodyn. 2011;30:360–365.CrossRefPubMed
19.
Zurück zum Zitat Wagg A, Khullar V, Marschall-Kehrel D et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013;61:185–193.CrossRefPubMed Wagg A, Khullar V, Marschall-Kehrel D et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013;61:185–193.CrossRefPubMed
20.
Zurück zum Zitat DuBeau CE, Kraus SR, Griebling TL et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014;191:395–404.CrossRefPubMed DuBeau CE, Kraus SR, Griebling TL et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014;191:395–404.CrossRefPubMed
21.
Zurück zum Zitat Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176:627–632. discussion 632. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176:627–632. discussion 632.
22.
Zurück zum Zitat Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology. 2006;68:17–28.CrossRefPubMed Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology. 2006;68:17–28.CrossRefPubMed
Metadaten
Titel
Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder
verfasst von
Alexandra I. Barsdorf
Martin Carlsson
Andrew G. Bushmakin
Sheila Quinn
Joseph C. Cappelleri
Andreas Pleil
Publikationsdatum
04.04.2017
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 12/2017
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-017-3305-8

Weitere Artikel der Ausgabe 12/2017

International Urogynecology Journal 12/2017 Zur Ausgabe

Urogynecology Digest

Urogynecology digest

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.